Will the Minister clarify that the vast majority of medical bodies feel that it is not a barrier to innovation, and that there are some important points where we need to protect patients from irresponsible innovation? We have to accept that there is a risk inherent in going down a route that would make that possible.
Access to Medical Treatments (Innovation) Bill
Proceeding contribution from
Sarah Wollaston
(Conservative)
in the House of Commons on Friday, 16 October 2015.
It occurred during Debate on bills on Access to Medical Treatments (Innovation) Bill.
About this proceeding contribution
Reference
600 c605Session
2015-16Chamber / Committee
House of Commons chamberLibrarians' tools
Timestamp
2021-11-04 13:31:33 +0000
URI
http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000401
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000401
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000401